Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge

Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge
March 31, 2022

During this session, our speakers Philippe de Jong and Kirian Claeyé will discuss the interesting judgment of the General Court in Polpharma v. EMA.


Our speakers will explain the judgment’s impact on whether a new medicinal product is entitled to a separate initial marketing authorisation, or belongs to the same global marketing authorisation as an earlier medicinal product. In other words, can the new medicinal product benefit from its own regulatory data protection period or not?

The judgment is furthermore not only interesting from a substantive point of view, but also contains some interesting examples on the pitfalls that may arise under EU procedural law in challenging decisions from the European Commission, whether in this area or others.

Contact

  • Philippe de Jong

    Partner

  • Kirian Claeyé

    Partner

Recommended articles

May 03, 2024

EU Court of Justice interprets import ban on Chinese animal products: fish oil for feed is not an exempted “fishery product”

On 21 March 2024, the EU Court of Justice (‘CJEU’) handed down its ruling in case C‑7/23, concerning a dispute between a feed company and the Federal Agency for the Safety of the Food Chain. The parties differed in their interpretation of an EU import ban on products of animal origin coming from China. The Council of State sought the CJEU’s guidance.

Read on
April 26, 2024

CJEU balances strict obligations for wholesalers of medicines with proportional penalties

On 21 September 2023, the EU Court of Justice ('CJEU’) handed down its ruling in the Apotheke B. case (C-47/22), and it is a good example of the high threshold set by the EU Court of Justice to uphold the Community Code’s main aim of protecting public health.

Read on
April 04, 2024

Hospital mergers no longer subject to the Belgian Competition Authority’s prior review

The legislator has now had the last word, by providing that, in principle, hospital mergers are no longer subject to the BCA’s prior review and approval.

Read on